This article was downloaded by: [Carnegie Mellon University] On: 21 January 2015, At: 04:18 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry Publication details, including instructions for

authors and subscription information: http://www.tandfonline.com/loi/Isyc20

One-Pot Synthesis of Rufloxacin

V. Cecchetti^a, A. Fravolini^a & F. Schiaffella^a ^a Istituto di Chimica, Farmaceutica e Tecnica Farmaceutica Università di Perugia, 06100, Perugia, Italy Published online: 23 Sep 2006.

To cite this article: V. Cecchetti , A. Fravolini & F. Schiaffella (1991) One-Pot Synthesis of Rufloxacin, Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry, 21:22, 2301-2308, DOI: 10.1080/00397919108021589

To link to this article: http://dx.doi.org/10.1080/00397919108021589

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions

ONE-POT SYNTHESIS OF RUFLOXACIN

V. Cecchetti, A. Fravolini^{*}, F. Schiaffella

Istituto di Chimica Farmaceutica e Tecnica Farmaceutica Università di Perugia, 06100 Perugia, Italy

ABSTRACT: Rufloxacin (MF-934) was prepared in one-pot synthesis in 61% yield by treatment of the 2,3,5-trifluoro-4-(4-methyl-1piperazinyl)-benzoyl acetate, first with N,N-dimethylformamide dimethyl acetal, then with 2-aminoethanethiol, followed by cyclization and hydrolysis.

Rufloxacin (MF-934) 9-fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de] [1,4] benzothiazine-6-carboxylic acid $(\underline{1})^1$ is a new potent antibacterial quinolone which, after



Author to whom correspondence should be addressed.

2301

Copyright © 1991 by Marcel Dekker, Inc.

CECCHETTI, FRAVOLINI, AND SCHIAFELLA

completing phase III, is ready to be marketed as a once-daily antibacterial quinolone².

The reported synthesis for rufloxacin requires several tedious and laborious steps^{1,3} that finally involve the solfoxidation of thiazinic sulfur of ethyl 10-chloro-9-fluoro-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazin-6-carboxylate in order to increase the reactivity of the aromatic nucleus to permit the regiospecific substitution of chlorine at C-10 with N-methylpipe-razine. Therefore this involves successive deoxigenation with PCl₂ after nucleophilic substitution.

We, herein, report a simple and shorter synthesis in a one-pot serial operation as follows: first conversion of 2,3,5-trifluoro-4-(4-methy)-1-piperaziny)-benzoyl acetate to dimethylacrylatederivative <u>2</u>, by treatment with N,N-dimethylformamide dimethylacetal, then reaction with 2-aminoethanethiol followed byintramolecular cyclization with NaH of obtained intermediate <u>3</u>and, finally, hydrolisis by water dilution and heating to give,after salification, rufloxacin hydrochloride (<u>1</u>) in 61% totalyield (Scheme I). The same reaction sequence was also carried outin single steps , isolating the various intermediates tocaracterize them.



<u>Scheme I</u>: ^a (MeO)₂CHNMe₂, toluene, Δ ; ^b SH(CH₂)₂NH₂, EtOH; ^c NaH, THF, 0 °C; ^d OH, H₂O, Δ .

EXPERIMENTAL SECTION

Melting points were determined in capillary tubes (Büchi melting point apparatus) and are uncorrected. Elemental analyes were performed on a Carlo Erba elemental analyzer, Model 1106, and the data for C, H and N are within $\pm 0.4\%$ of the theoretical values. ¹H NMR spectra were recorded on a Bruker AC 200 spectrometer with CDCl₃ as solvent and Me₄Si as internal standard. Reagents and solvent were purchased from common commercial suppliers and were

CECCHETTI, FRAVOLINI, AND SCHIAFELLA

used as received. Column chromatography separations were carried out on Merck silica gel 40 (mesh 70-230). Organic solutions were dried over anhydrous Na₂SO₄ and concentrated with Büchi rotary evaporator at low pressure.

9-Fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido-[1, 2,3-de][1,4]benzothiazine-6-carboxylic acid hydrochloride (<u>1</u>) N,N-Dimethylformamide dimethyl acetal (1.2 mL, 9.1 mmol) was added to a solution of ethyl 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)-benzoyl acetate⁴ (2.0 g, 5.8 mmol) in toluene (10 mL). The mixture was heated at reflux for 1 h and concentrated to dryness to give a viscous oil which was dissolved in EtOH (20 mL). To this ethanolic solution, cooled in an ice-bath, a solution of

2-aminoethanethiol (0.6 g, 7.8 mmol) and EtOH (10 mL) was then added. The resulting mixture was stirred at room temperature for 5 h and then concentrated to dryness to give a viscous oil which was dissolved in dry THF (30 mL).

Sodium hydride (60% NaH in oil suspension 0.5 g, 12.5 mmol) was then added to the above solution cooled in an ice-bath. The suspension was stirred under nitrogen atmosfere at 0 °C for 15 min and followed by the addition of water (30 mL). The resulting suspension was refluxed for 15 min until dissolution occurred. The cooled solution was then neutralized with AcOH and concentrated to dryness. Ethanol (20 mL) was added to the residue and the insoluble material was filtered off and discarded. A saturated solution of HCL gas in diethyl ether was added to the above clear solution and the separated solid was collected by filtration and crystallized from 7:3 EtOH/H₂0 to give 0.7 g (61% total yield) of $\underline{1}$, mp 322-324 °C (lit.1, mp 322-324 °C).

Ethyl 2-[2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)-benzoyl]-3dimethylaminoacrylate (<u>2</u>)

A mixture of ethyl 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)benzoylacetate⁴ (2.0 g, 5.8 mmol) and N,N-dimethylformamide dimethyl acetal (1.2 mL, 9.1 mmol) in toluene (10 mL) was refluxed for 1 h and then concentrated to dryness. The residual viscous oil was purified by fast filtration on silica gel column, eluting with CHCl₃ to give 2.11 g (91%) of viscous oil <u>2</u> as a 7:3 or 3:7 mixture of (E)- and (Z)-isomers, as revealed by its ¹H NMR spectrum. ¹H NMR δ 1.05 and 1.10 (3H, each t, J=7 Hz, CH₂CH₃), 2.40 (3H, s, NCH₃), 2.50-2.70 (4H, m, piperazinic CH₂), 3.10 [6H, bs, N(CH₃)₂], 3.25-3.50 (4H, m, piperazinic CH₂), 4.05 and 4.10 (2H, each q, J=7 Hz, CH_2CH_3), 7.00-7.30 (1H, m, aromatic H), 7.75 and 7.90 (1H, each s, olefinic H).

Ethyl 2-[2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)-benzoyl]-3-(1mercaptoeth-2-ylamino)-acrylate (<u>3</u>)

A solution of 2-aminoethanethiol (0.6 g, 7.8 mmol) in EtOH (5 mL) was added to a cooled solution of $\underline{2}$ (2.0 g, 5.0 mmol) in EtOH (20 mL). The reaction mixture was stirred at room temperature for 5 h and then concentrated to dryness. The residual viscous oil was purified by silica gel column chromatography, eluting with CHCl₃ to give 1.7 g (77%) of viscous oil $\underline{3}$ as a 7:3 or 3:7 mixture of (E)- and (Z)-isomers. ¹H NMR & 0.90-1.35 (4H, m, CH₂CH₃ and SH), 2.45 (3H, s, NCH₃), 2.50-2.65 (4H, m, piperazinic CH₂), 2.85-3.10 (2H, m, NCH₂CH₂S), 3.25-3.45 (4H, m, piperazinic CH₂), 3.65-3.90 (2H, m, NHCH₂CH₂S), 4.05 and 4.10 (2H, each q, J=7 Hz, CH₂CH₃), 6.75-7.05 (1H, m, aromatic H), 7.95 and 8.05 (1H, each d, J=15 Hz, olefinic H), 9.30-9.70 and 10.80-11.00 (1H, each m, NH).

Ethyl 9-fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7Hpyrido [1,2,3-de][1,4]benzothiazine-6-carboxylate (<u>4</u>) Sodium hydride (60% NaH in oil suspension 0.35 g, 8.75 mmol) was slowly added to a cooled solution of <u>3</u> (1.5 g, 3.5 mmol) in dry THF (30 mL). The reaction mixture was stirred at 0 °C for 15 min under nitrogen athmosphere, then poured into ice-water (100 mL) and extracted with CHCl₃. The organic phases were combined, washed with water , dried and evaporated to dryness. The solid residue was crystallized from EtOH to give 1.2 g (88%) of <u>4</u>, mp 160-163 °C. ¹H NMR & 1.40 (3H, t, J=7 Hz, CH₂CH₃), 2.35 (3H, s, NCH₃), 2.50-2.70 (4H, m, piperazinic CH₂), 3.05-3.50 (6H, m, piperazinic CH₂ and NCH₂CH₂S), 4.35 (2H, q, J=7 Hz, CH₂CH₃), 4.50-4.75 (2H, m, NCH₂CH₂S), 7.80 (1H, d, J=12 Hz, aromatic H), 8.30 (1H, s, olefinic H).

9-Fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido-[1, 2,3-de][1,4]benzothiazine-6-carboxylic acid hydrochloride (<u>1</u>) A stirred suspension of <u>4</u> (0.2 g) in 15% NaOH (10 mL) was refluxed for 15 min until dissolution occurred. The cooled mixture was neutralized with AcOH and then evaporated to dryness. To the solid residue, EtOH (10 mL) was added and the insoluble material filtered off and discarded. A saturated solution of HCl gas in diethyl ether was added to the above filtrate and the separated solid was collected by filtration and crystallized from 7:3 EtOH/H₂O to give 0.16 g (86%) of <u>1</u>.

REFERENCES

- Cecchetti, V., Fravolini, A., Fringuelli, R., Mascellani, G., Pagella, P., Palmioli, M., Segre, G. and Terni, P., J. Med. Chem., 1987, <u>30</u>, 465.
- 2. Drugs Future, 1990, <u>15</u>, 763.
- a) Mascellani, G., Fravolini, A., Terni, P., (Mediolanum Farmaceutici), Jpn Kokai Tokkyo Koho 60,208,987; Chem. Abstr. 1986, <u>104</u>, 207290. b) Terni, P., Rugarli, P.L., Maiorana, S., Pagella, P., Fusco, R., Eur. Pat. Appl. EP 252,352; Chem. Abstr. 1988, <u>109</u>, 129034.
- Egawa, H., Miyamoto, T., Matsumoto, J.-I., Chem. Pharm. Bull., 1986, <u>34</u>, 4098.

(Received in UK 24 June, 1991)